VKTX Stock Price Predictions 2023 2024 2025 2030 : Viking Therapeutics Inc is a clinical-stage biopharmaceutical company that focuses on the development of therapies for metabolic and endocrine disorders. The company’s stock is listed on the NASDAQ stock exchange under the ticker symbol VKTX. Viking Therapeutics has a number of drugs in its pipeline, including VK5211, a non-steroidal selective androgen receptor modulator (SARM) for the treatment of muscle wasting and osteoporosis, and VK2809, a thyroid hormone receptor beta agonist for the treatment of hypercholesterolemia and non-alcoholic fatty liver disease

. In 2021, the company announced positive results from a phase 2 clinical trial of VK2809, which showed significant improvements in multiple metabolic parameters in patients with hypercholesterolemia. As of 2022, Viking Therapeutics has a market capitalization of approximately $720 Million.

VKTX Stock Price Predictions 2023 2024 2025 2030 & 2035

VKTX Stock Forecast 2023 2025 2030	Price $
VKTX Stock Forecast 2023	$11 – $13
VKTX Stock Forecast 2024	$14 – $18
VKTX Stock Forecast 2025	$20 – $22
VKTX Stock Forecast 2030	$25 – $35
VKTX Stock Forecast 2035	$40 – $48
VKTX Stock Forecast 2040	$65 – $85

VKTX Stock Forecast 2023 | VKTX Stock Price Predictions 2023

As of June 2022, Viking Therapeutics Inc ( NASDAQ: VKTX ) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for metabolic and endocrine disorders. The company has a number of promising drug candidates in its pipeline, including VK2809, a thyroid hormone receptor agonist for the treatment of non-alcoholic steatohepatitis (NASH) and hypercholesterolemia.

Based on the company’s current clinical trial data and market trends, we believe that Viking Therapeutics Inc has the potential to see significant growth in the coming years. The NASH market is expected to reach $20 billion by 2025, and VK2809 has shown promising results in Phase 2 clinical trials. Additionally, the company’s other drug candidates, such as VK0214 for the treatment of X-linked adrenoleukodystrophy, also have the potential to be successful in the market.

However, as with any clinical-stage biotech company, there are also risks to consider. Viking Therapeutics Inc is currently in the early stages of clinical development, and it is uncertain if their drug candidates will be approved by regulatory agencies and successfully commercialized.

Overall, we believe that Viking Therapeutics Inc has a positive outlook and could see significant growth in the near future. Investors should carefully consider the potential risks and opportunities before making any investment decisions.

VKTX Stock Forecast 2024 | VKTX Stock Price Predictions 2024

It is difficult to accurately predict the future performance of a stock, but based on current trends and market analysis, it is expected that Viking Therapeutics Inc (NASDAQ: VKTX) will have a strong performance in 2024.

Currently, the company is focused on developing innovative therapies for metabolic and endocrine disorders. Their pipeline includes several promising candidates that are in various stages of clinical development, including a phase 2 trial for a treatment for nonalcoholic Steatohepatitis (NASH).

Read – Amazon Stock Price Predictions 2023 2024 2025 2030 

Additionally, the company has a strong financial position, with a solid balance sheet and a history of revenue growth. This, combined with the increasing demand for treatments for metabolic and endocrine disorders, suggests that Viking Therapeutics Inc has strong potential for growth in the coming years.

Overall, it is expected that Viking Therapeutics Inc will continue to generate positive results in 2024 and beyond, making it a potentially attractive investment opportunity for those looking to add a biotech stock to their portfolio. As always, it is important to do thorough research and consult with a financial Advisor before making any investment decisions.

VKTX Stock Price Predictions 2025 | VKTX Stock Forecast 2025

According to our analysts, Viking Therapeutics has strong potential for growth in the coming years. The NASH market is expected to reach over $20 billion by 2025, and VK2809 has shown promising results in early clinical trials. Additionally, the company has a number of other drugs in development for the treatment of hypothyroidism and obesity, which also have significant market potential.

Our stock forecast for Viking Therapeutics in 2025 is a strong buy. We expect the company’s revenue to increase significantly as its drug pipeline advances through clinical trials and potentially gains regulatory approval. In addition, we believe that the company’s focus on developing therapies for high unmet medical needs will drive long-term growth and shareholder value. Overall, we believe that Viking Therapeutics is well-positioned to capitalize on the growing demand for innovative treatments for metabolic and endocrine disorders.

VKTX Stock Predictions 2030 | VKTX Stock Forecast 2030

The stock forecast for Viking Therapeutics Inc (NASDAQ: VKTX) in 2030 is a positive one. This company is focused on developing novel therapies for metabolic and endocrine disorders, and has several promising candidates in its pipeline.

One of the key drivers for VKTX in 2023 is the potential approval and launch of its drug VK2809. This drug is being developed for the treatment of non-alcoholic fatty liver disease (NAFLD) and hypercholesterolemia, and has shown promising results in clinical trials. If approved, VK2809 has the potential to be a blockbuster drug, with a large market opportunity and significant revenue potential.

Another potential catalyst for VKTX in 2030 is the advancement of its other pipeline candidates. The company has several other drugs in development for the treatment of various metabolic and endocrine disorders, including VK0214 for the treatment of type 2 diabetes, VK0612 for the treatment of hypothyroidism, and VK5211 for the treatment of sarcopenia. If any of these drugs show promising results in clinical trials and are eventually approved, it could also drive significant revenue for the company.

Overall, the outlook for VKTX in 2030 is bright, with a strong pipeline and potential for multiple revenue streams. While there are always risks in the biotech industry, VKTX’s focus on metabolic and endocrine disorders is a growing market with high demand, and the company’s progress so far suggests that it has the potential to become a major player in this space.

VKTX Stock Forecast 2023 2025 2030 – FAQs